Related Experiment Videos
In vivo antitumor activity of tetrahydrobenz(a)anthraquinone derivatives
C E Morreal1, D K Sinha, C J White
1Breast Cancer Research Unit, Roswell Park Memorial Institute, Buffalo, New York 14263.
Anticancer Research
|July 1, 1990
Abstract:
Female rats bearing DMBA induced mammary carcinomas were treated with a new anthraquinone derivative related to mitoxantrone. The drug was administered at a dose of 5 mg/kg daily for 10 days. Tumor regression was noted in 78% of the animals with growth rate reduced from +74.91% to -12.60%. The results demonstrate that replacement of a polar hydroxy group of mitoxantrone with a nonpolar hydrocarbon moiety does not impair its antitumor activity and in fact may influence its availability to endocrine systems.